FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
60.718,64 +567,10 (+0,94%)
Next Science Limited (NXS.AX)
Next Science Limited
Australia Square
Level 14 264-278 George Street
Sydney, NSW 2000
Australia
61 4 1229 2977
https://www.nextscience.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno:
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Mr. Harry Thomas Hall | MD, CEO & Director | 651,23k | N/D | N/D |
| Dr. Matthew Franco Myntti | Founder & CTO | 573,59k | N/D | N/D |
| Marc Zimmerman | Chief Financial Officer | 534,42k | N/D | N/D |
| Mr. Jon Swanson | Chief Operating Officer | 413,06k | N/D | N/D |
| Mr. Robert Bell | Senior Vice President of North American Sales | N/D | N/D | N/D |
| Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Secretary | N/D | N/D | N/D |
Descrizione
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Governance aziendale
L'ISS Governance QualityScore di Next Science Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.
